APA (7th ed.) Citation

S, M., J, H., N, N., T, B., I, V. E., C, H. H., . . . B, N. (2024). Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study. Influenza and other respiratory viruses, 18(4), e13292. https://doi.org/10.1111/irv.13292

Chicago Style (17th ed.) Citation

S, Monge, et al. "Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study." Influenza and Other Respiratory Viruses 18, no. 4 (2024): e13292. https://doi.org/10.1111/irv.13292.

MLA (9th ed.) Citation

S, Monge, et al. "Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study." Influenza and Other Respiratory Viruses, vol. 18, no. 4, 2024, p. e13292, https://doi.org/10.1111/irv.13292.